Uncategorized
Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy
PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that the U.S. FDA completed its filing review and accepted the company’s New Drug Application (NDA) for avacincaptad pegol (ACP).